# Probiotics-enhanced kynurenic acid mitigates cisplatin-induced nephrotoxicity in mice

**Authors:** Kangxin Li, Hui Yuan, Jieyan Wang, Jiaxin Ou, Guiming Chen, Shiyu Li, Qudi Qiao, Qiannan Deng, Shu-Lan Qin

PMC · DOI: 10.1016/j.isci.2026.115053 · iScience · 2026-02-17

## TL;DR

This study shows that kynurenic acid, boosted by probiotics, can protect mice from kidney damage caused by cisplatin chemotherapy.

## Contribution

The novel finding is that probiotics can enhance endogenous kynurenic acid to provide comparable kidney protection as high-dose kynurenic acid.

## Key findings

- Kynurenic acid reduces cisplatin-induced kidney injury through multiple mechanisms.
- Probiotics increase endogenous kynurenic acid levels, offering comparable renal protection.
- KYNA's protective effects involve Nrf2 pathway activation and suppression of inflammation and apoptosis.

## Abstract

Cisplatin chemotherapy is limited by dose-dependent nephrotoxicity. This study investigates the nephroprotective potential of kynurenic acid (KYNA), a tryptophan metabolite, against cisplatin-induced renal injury. Initial metabolic results revealed significant elevation of serum KYNA levels in cisplatin-treated mice, suggesting endogenous compensatory mechanisms. Systematic pharmacological evaluation demonstrated that intraperitoneal administration (i.p.) of KYNA (100, 250, and 500 mg/kg) dose-dependently attenuated cisplatin-induced nephrotoxicity through multi-modal mechanisms, including the suppression of pro-inflammatory cytokines via NF-κB p65 pathway inhibition and MAPKs dephosphorylation, reduction of renal apoptosis through Bcl-2 family rebalancing and caspase-3 cascade inhibition, and enhancement of antioxidant defenses via Nrf2 pathway activation with concomitant upregulation of downstream effectors. We further established that probiotic supplementation elevated endogenous KYNA production, achieving comparable renoprotection to high-dose KYNA monotherapy. Our findings delineate KYNA’s multi-modal mechanisms against cisplatin nephrotoxicity and demonstrate that the probiotic-mediated modulation of host metabolism represents a viable strategy to enhance endogenous KYNA for renal protection.

•Kynurenic acid mitigates cisplatin nephrotoxicity via multi-modal mechanisms•Probiotics elevate endogenous kynurenic acid to protect kidneys•Study reveals a gut microbiota-KYNA-kidney protective axis•KYNA’s renoprotection requires the activation of the Nrf2 pathway

Kynurenic acid mitigates cisplatin nephrotoxicity via multi-modal mechanisms

Probiotics elevate endogenous kynurenic acid to protect kidneys

Study reveals a gut microbiota-KYNA-kidney protective axis

KYNA’s renoprotection requires the activation of the Nrf2 pathway

Molecular biology; Neuroscience; Microbiology

## Linked entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], Casp3 (caspase 3) [NCBI Gene 12367], GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551]
- **Chemicals:** cisplatin (PubChem CID 5460033), kynurenic acid (PubChem CID 3845), KYNA (PubChem CID 3845)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Keap1 (kelch-like ECH-associated protein 1) [NCBI Gene 50868] {aka INRF2, mKIAA0132}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Cxcl2 (C-X-C motif chemokine ligand 2) [NCBI Gene 20310] {aka CINC-2a, GROb, Gro2, MIP-2, MIP-2a, Mgsa-b}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, Havcr1 (hepatitis A virus cellular receptor 1) [NCBI Gene 171283] {aka KIM-1, TIM-1, Tim1, Timd1}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Nqo1 (NAD(P)H dehydrogenase, quinone 1) [NCBI Gene 18104] {aka Dia4, Dtd, Nmo-1, Nmo1, Nmor1, Ox-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Ido1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 15930] {aka Ido, Indo}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Gclm (glutamate-cysteine ligase, modifier subunit) [NCBI Gene 14630] {aka Gcmc, Glclr}, Katnb1 (katanin p80 (WD40-containing) subunit B 1) [NCBI Gene 74187] {aka 2410003J24Rik, KAT}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, C1ql3 (C1q-like 3) [NCBI Gene 227580] {aka 1110065A22Rik, Adij, C1ql, C1qtnf13, CTRP13, K100}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Cish (cytokine inducible SH2-containing protein) [NCBI Gene 12700] {aka CIS-1, CIS1, Cis, F17, F23, SOCS}, Lcn2 (lipocalin 2) [NCBI Gene 16819] {aka 24p3, NRL, Sip24}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709]
- **Diseases:** multiorgan failure (MESH:D051437), neuropsychiatric disorders (MESH:D001523), neurotoxic (MESH:D020258), diabetes (MESH:D003920), malignancies (MESH:D009369), multiorgan toxicity (MESH:D064420), osteoporosis (MESH:D010024), ischemic and chronic kidney disease (MESH:D051436), atrophy (MESH:D001284), neurodegeneration (MESH:D019636), headaches (MESH:D006261), inflammation (MESH:D007249), acute injury (MESH:D001930), ischemia (MESH:D007511), diabetic nephropathy (MESH:D003928), metabolic disorders (MESH:D008659), renal (MESH:D006030), sepsis (MESH:D018805), MOD (MESH:C564833), inflammatory cytokines (MESH:D000080424), hepatic steatosis (MESH:D005234), multi-organ dysfunction (MESH:D009102), multi-organ damage (MESH:D000092124), kidney injury (MESH:D007674), AKI (MESH:D058186), carcinogenesis (MESH:D063646), esophageal, lung, and ovarian cancers (MESH:D010051)
- **Chemicals:** butyrate (MESH:D002087), KYNA (MESH:D007736), corn oil (MESH:D003314), nitrogen (MESH:D009584), MDA (MESH:D008315), HE (-), Cisplatin (MESH:D002945), paraffin (MESH:D010232), Curcumin (MESH:D003474), saline (MESH:D012965), hematoxylin (MESH:D006416), eosin (MESH:D004801), PBS (MESH:D007854), PVDF (MESH:C024865), KYN (MESH:D007737), SDS (MESH:D012967), tryptophan (MESH:D014364), 3-hydroxykynurenine (MESH:C005045), ethanol (MESH:D000431), creatinine (MESH:D003404), formalin (MESH:D005557), DMSO (MESH:D004121), quinolinic acid (MESH:D017378), ROS (MESH:D017382), GSH (MESH:D005978), urea nitrogen (MESH:C530477), paraformaldehyde (MESH:C003043), lipid (MESH:D008055), TRIZOL (MESH:C411644)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Mus musculus (house mouse, species) [taxon 10090], Lacticaseibacillus rhamnosus (species) [taxon 47715], Homo sapiens (human, species) [taxon 9606], Bifidobacterium longum (species) [taxon 216816], Limosilactobacillus reuteri (species) [taxon 1598], Bifidobacterium bifidum (species) [taxon 1681]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12969009/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12969009/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12969009/full.md

---
Source: https://tomesphere.com/paper/PMC12969009